Share Name Share Symbol Market Type Share ISIN Share Description
Abcam Plc LSE:ABC London Ordinary Share GB00B6774699 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  61.00 4.9% 1,306.00 1,307.00 1,309.00 1,328.00 1,238.00 1,238.00 779,349 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 259.9 56.4 22.0 59.4 2,685

ABCAM PLC Total Voting Rights

01/10/2019 2:22pm

UK Regulatory (RNS & others)


RNS Number : 3781O


01 October 2019

 For immediate release   01 October 2019 


("Abcam" or "Company")

Total Voting Rights - Voting Rights and Capital

In conformity with the Disclosure Rules and Transparency Rules, provision 5.6.1, the Company notifies the market of the following:

The Company's issued share capital consists of 205,790,898 Ordinary Shares of 0.2p each with voting rights. The Company does not hold any shares in Treasury.

The above figure of 205,790,898 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Date of Notification: 01 October 2019.

For further information please contact:

                                                         + 44 (0) 1223 696 
Abcam                                                                  000 
Marc Perkins, Company Secretary 
J.P.Morgan Cazenove - Nominated Adviser & Corporate       + 44 (0) 20 7742 
 Broker                                                               4000 
James Mitford / Jonty Edwards 
  FTI Consulting                                           +44 (0) 20 3727 
  Ben Atwell / Brett Pollard / Natalie Garland-Collins     1000 

Notes to Editors

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's thirteen locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit and

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

October 01, 2019 09:22 ET (13:22 GMT)

1 Year Abcam Chart

1 Year Abcam Chart

1 Month Abcam Chart

1 Month Abcam Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191117 05:22:20